Endo Health Solutions 8K FTN Midwest Health Care Conference | ENDP 6 Jun 07

2007 Endo Pharmaceuticals

ENDO PHARMACEUTICALS

FTN Midwest Health Care Conference

June 6, 2007

Exhibit 99.1

Accelerating Our Growth

2007 Endo Pharmaceuticals

Forward-Looking Statements

Except

for

the

historical

information

contained

herein,

this

presentation

contains

“forward-looking

statements”

within

the

meaning

the

Private

Securities

Litigation

Reform

Act

1995.

Because

these

statements

involve

number

risks

and

uncertainties,

actual

future

results

may

differ

materially

from

those

expressed

implied

such

forward-looking

statements.

Factors

that

could

cause

contribute

such

differences

include,

but

are

not

limited

to,

the

difficulty

predicting

FDA

approvals,

results

clinical

trials

new

products,

acceptance

and

demand

for

new

pharmaceutical

products,

challenges

relating

intellectual

property

protection,

the

impact

competitive

products

and

pricing,

the

timely

development

and

launch

new

products,

determination

that

are

engaging

inappropriate

sales

marketing

activities,

including

promoting

the

"off-label"

use

our

products,

and

the

risk

factors

listed

from

time

the

Company’s

SEC

reports,

including

the

Company’s

Annual

Report

Form

10-K

for

the

fiscal

year

ended

December

31,

2006.

Accelerating Our Growth

2007 Endo Pharmaceuticals

Endo Pharmaceuticals

–

Leader in

Pain Management

Specialty pharma company with market leadership in pain

management

•

Analgesics were the fourth-largest prescription drug market in 2006

•

Opioids represented 80% of analgesic prescriptions

Proven commercial capability

•

Specialty and PCP sales and marketing teams

Pipeline focused on delivery and execution

•

Two NDAs approved in 2006; expect additional sNDA in Aug. ‘07

Strong financial condition

Accelerating Our Growth

2007 Endo Pharmaceuticals

Growth Strategy

Maximize value of established brands

Expand through licensing and acquisition while remaining

specialist driven

•

Diversify revenue stream

•

Expand balanced, sustainable pipeline

Strengthen leadership position in Pain Management and drive

continued expansion into additional therapeutic areas such as

neurology and supportive care oncology

Accelerating Our Growth

2007 Endo Pharmaceuticals

2007 –

Investing in the Future

Increasing promotional support behind key brands:

•

Expanded managed markets team

•

Expanded clinical liaison team

•

Conducting comprehensive physician education and patient

outreach programs

Optimizing expanded sales force of 590 representatives

Accelerating R&D investment behind ketoprofen patch,

Rapinyl

3285,

and

sufentanil

patch

Enhancing infrastructure to sustain our growth through 2010:

•

New systems, processes, people

Accelerating Our Growth

2007 Endo Pharmaceuticals

2007 Key Objectives

Achieve $1.025 to $1.050 billion in net sales

•

Deepen Lidoderm

penetration in PHN market

–

Guidance of $650MM to $675MM

•

Accelerate

sales

trajectory

for

the

Opana

franchise

–

Guidance of $85MM to $105MM

Obtain

FDA

approval

for

Frova

the

prophylaxis

indication

Accelerate development of our current pipeline to meet market

needs and optimize target product profiles

Pursue strategic licensing and acquisition opportunities that

expand beyond pain but allow us to retain our focus on the

specialty physician community

Accelerating Our Growth

2007 Endo Pharmaceuticals

$200

$400

$600

$800

$1,000

$1,200

2002

2003

2004

2005

2006

2007*

Net Sales

Net Income

Consistent Financial Growth

$399.0

$595.6

$615.1

$820.2

$30.8

$69.8

$143.3

$202.3

$909.7

$1,037.0

$137.8

(millions, except per share)

Diluted EPS $0.30 $0.53 $1.08

$1.52 $1.03 **

* Represents mid-point of company guidance ** Includes $0.62 in one-time, non-cash items

Accelerating Our Growth

2007 Endo Pharmaceuticals

Lidoderm

A True Success Story

Lidocaine 5% topical patch

•

Acts locally -

therapeutically meaningful

blood levels

First FDA-approved drug for

treatment of pain of PHN

Provides analgesia (but no

anesthesia) directly to

affected nerves

Easy and convenient to use

Accelerating Our Growth

2007 Endo Pharmaceuticals

Lidoderm

Barriers to Potential Generics

Currently protected by five (5) Orange Book-listed patents until

2015:

•

Two method of use patents expiring 2009

•

Two method of use patents expiring 2012

•

Formulation patent expiring 2015

2012 method of use patents cover use of lidocaine-containing

patch in indication of PHN

Lidocaine-containing

topical

product

that

does

not

numb

the

skin

•

Unique attribute covered under patent estate

•

Believe this would be requirement for generic substitution

Submitted Citizen Petition December 19, 2006

•

Requests that FDA apply to any generic challenger

existing

bioequivalence regulations for topical products

Accelerating Our Growth

2007 Endo Pharmaceuticals

$178

$309

$419

$663

$567

$200

$400

$600

$800

2003

2004

2005

2006

2007*

Lidoderm

Continuing Net Sales Growth

($ in millions)

*Represents mid-point of company guidance

Accelerating Our Growth

2007 Endo Pharmaceuticals

Opana

Franchise

Accelerating Our Growth

2007 Endo Pharmaceuticals

Opana

ER –

Broad Label

Broad indication: For the relief of moderate-to-severe pain in patients

requiring continuous, around-the-clock opioid treatment for an extended

period of time

First time oxymorphone available in oral ER formulation

Proven efficacy in broad range of appropriate pain patients

Key messages of clinical differentiation

•

Twice-daily dosing

•

Effective pain control shown at stable dose for three months in

clinical

trials

underscores

durability

Opana

ER’s

analgesic

effect

•

Generally well tolerated when titrated effectively*

* Most common adverse events (> 10%) in trials were nausea, constipation, dizziness, vomiting, pruritus,

somnolence, headache, increased sweating, and sedation

Accelerating Our Growth

2007 Endo Pharmaceuticals

Opana

Franchise -

Targeted

Commercial Strategy

Opana

competes

$3.2

billion

U.S.

long-acting

strong

opioid market

Combined

Opana

and

Opana

net

sales

guidance

for

2007

is $85 million to $105 million

•

Expect to reach 10,000 Rx’s per week by year-end

Expanded

sales

force

mid-2006

220

reps

promote

Opana

and

Opana

approximately

90,000

physicians

Implemented Risk Minimization Action Plan for appropriate

patient utilization

Full range of promotional activities now underway

Accelerating Our Growth

2007 Endo Pharmaceuticals

Key Opana

Marketing and Promotional

Activities

Instituted Specialty Force II to provide double coverage on 6,600 high-

decile specialists

Expanded appropriate patient access through direct-discount programs

Instituted managed care contracting strategy to achieve parity or better

formulary status

•

Tripled size of managed markets group to extend reach to regional

and local plans

Introduced new sales/marketing initiatives

•

Journal ads

•

Reprints of peer-reviewed journal articles

•

Speaker dinner programs

•

Major commercial presence at key medical meetings

Accelerating Our Growth

2007 Endo Pharmaceuticals

Opana

ER TRx Launch Comparison

Accelerating Our Growth

2007 Endo Pharmaceuticals

Frova

Profile

Triptan indicated for acute

treatment of migraine

headaches in adults

Market differentiation based

on low recurrence rate, long

half-life

Potential label expansion for

menstrual migraine

prophylaxis represents

significant market

opportunity

2006 Net sales $40.6 million

Accelerating Our Growth

2007 Endo Pharmaceuticals

Robust Development Pipeline

(1)

Licensed marketing rights

(2)

Licensed marketing and development rights

Phase I

Phase II

Phase III

Filed

Pre-

clinical

Undisclosed

Sufentanil Patch

(2)

(Transdermal -

Chronic Pain)

EN 3285

(Oral Rinse for Oral Mucositis)

Rapinyl

TM (2)

(Breakthrough Cancer Pain)

Ketoprofen Patch

(2)

(Topical -

Soft Tissue Injuries)

Frova

(1)

(Menstrual Migraine)

Product

Accelerating Our Growth

2007 Endo Pharmaceuticals

Frova

MM Prophylaxis:

Exciting Near-Term Opportunity

PDUFA date 8/19/07

Substantial data package:

•

Two double-blind, placebo-controlled studies in Menstrual Migraine

(MM) prophylaxis; long-term open-label safety & tolerance study

Pivotal efficacy studies:

•

Frova

taken for six days, starting two days prior to onset of

expected MM headache

•

Primary efficacy endpoint: reduction in incidence of MM headache

–

p <0.0001 to p < 0.01 (vs. placebo)

•

Secondary endpoints --

reduction in severity and duration of MM

headache --

also achieved

Accelerating Our Growth

2007 Endo Pharmaceuticals

Ketoprofen Patch

Topical patch for localized treatment of acute pain from soft-

tissue injuries such as tendonitis/bursitis, joint sprains or strains

Ketoprofen (NSAID) currently only available in U.S. in oral form

Would compete in ~$2.5 billion soft-tissue injury market primarily

consisting of NSAIDs and COX-IIs

Anticipated benefits include:

•

Bypassing bloodstream to minimize GI and

cardiovascular side effects

•

Local, targeted pain control

•

Convenience of once-daily dosing

Phase III trials ongoing; projected NDA filing date 1H 2008

Accelerating Our Growth

2007 Endo Pharmaceuticals

Ketoprofen Patch –

Study Update

Four Phase III trials

•

Two efficacy studies to evaluate treatment of pain associated with

tendonitis or bursitis of the shoulder, elbow or knee

•

One efficacy study to evaluate treatment of pain associated with

ankle sprain or strain

•

One study in patients with osteoarthritis flare of the knee, primarily

designed to collect long-term safety data

Accelerating Our Growth

2007 Endo Pharmaceuticals

Rapinyl

Oral, fast-dissolving sublingual fentanyl tablet

Intended for the treatment of breakthrough cancer pain

•

Expected to compete with Actiq and Fentora

Anticipated benefits include:

•

Fast onset of action

•

Enhanced absorption characteristics

•

Added patient convenience

Phase III trials ongoing

Projected NDA filing date 1H 2008

Accelerating Our Growth

2007 Endo Pharmaceuticals

EN 3285

Key product obtained in RxKinetix acquisition

Patent-protected oral rinse formulated using proprietary

ProGelz

delivery platform for prevention of oral mucositis (OM)

About 400,000 patients per year in U.S. develop OM

•

Only current FDA-approved treatment is IV infusion

Anticipated benefits of EN 3285 include:

•

Ease of use for patients

•

No systemic side effects

Accelerating Our Growth

2007 Endo Pharmaceuticals

Transdermal Sufentanil Patch

Intended for moderate-to-severe chronic pain

Follow-on to Duragesic

Anticipated benefits include:

•

Convenience/compliance of seven-day dosing vs. three-day dosing

•

Smaller patch --

20% the size of Duragesic

Phase I product characterization ongoing

Phase II trials anticipated to begin in 1H 2007

Accelerating Our Growth

2007 Endo Pharmaceuticals

Upcoming Key Milestones

Expanding a solid platform for sustainable growth:

Sufentanil Patch

Phase II

Ketoprofen

Patch

NDA Filing

Opana

and

Opana

Launch

EN 3285

Phase II/III

Acquisitions/

In-licensing

Rapinyl™

NDA

Filing

Ongoing

1H’07

2H’07

1H’08

Frova

FDA Action

Letter

Accelerating Our Growth

2007 Endo Pharmaceuticals

Summary

Market leader in pain management

Well-developed commercial capability

Very broad and deep pipeline

Strong financial condition

Sustainable strategy for growth

2007 Endo Pharmaceuticals

ENDO PHARMACEUTICALS

Nasdaq: ENDP

Endo Health Solutions (ENDP) Inactive 8-KFTN Midwest Health Care Conference